OBJECTIVE: To evaluate the effects of oral nonsteroidal antiinflammatory drugs (NSAIDs) on C-reactive protein (CRP) levels in rheumatoid arthritis (RA) patients, with a prespecified focus on the different NSAIDs. METHODS: We performed a systematic search in Medline via PubMed, the Cochrane Central Register of Controlled Trials, EMBase via OVID, the Institute for Scientific Information Web of Science, and other sources. Eligible trials were parallel-group, randomized, placebo-controlled trials of oral NSAID therapy in RA patients for which there were extractable CRP data. Standardized mean differences (SMDs) with 95% confidence intervals (95% CIs) were calculated from the differences in means of CRP levels between groups (active treatment minus placebo) divided by the pooled SDs. For the meta-analysis, a random-effects model was used to estimate the overall change in CRP level, and stratified analysis was used to examine differences among NSAIDs. RESULTS: We included 19 trials of 10 different NSAIDs. Overall, NSAIDs showed no effect on the CRP level (SMD 0.01 [95% CI -0.03, 0.06], P = 0.62). However, the prespecified stratified analysis indicated varying effects on the CRP level according to the different NSAIDs; lumiracoxib caused a statistically significant and consistent (I(2) = 0%) increase in the CRP level (SMD 0.13 [95% CI 0.01, 0.25], P = 0.037), whereas naproxen caused a statistically significant and consistent (I(2) = 0%) decrease in the CRP level (SMD -0.11 [95% CI -0.20, -0.02], P = 0.022). CONCLUSION: Overall, NSAIDs have no effect on the CRP level. However, the nonselective NSAID naproxen was associated with a significant decrease in the CRP level, whereas the cyclooxygenase 2-selective NSAID lumiracoxib was associated with a significant increase in the CRP level. This finding is interesting considering the suspected influence of NSAIDs on cardiovascular complications.
OBJECTIVE: To evaluate the effects of oral nonsteroidal antiinflammatory drugs (NSAIDs) on C-reactive protein (CRP) levels in rheumatoid arthritis (RA) patients, with a prespecified focus on the different NSAIDs. METHODS: We performed a systematic search in Medline via PubMed, the Cochrane Central Register of Controlled Trials, EMBase via OVID, the Institute for Scientific Information Web of Science, and other sources. Eligible trials were parallel-group, randomized, placebo-controlled trials of oral NSAID therapy in RApatients for which there were extractable CRP data. Standardized mean differences (SMDs) with 95% confidence intervals (95% CIs) were calculated from the differences in means of CRP levels between groups (active treatment minus placebo) divided by the pooled SDs. For the meta-analysis, a random-effects model was used to estimate the overall change in CRP level, and stratified analysis was used to examine differences among NSAIDs. RESULTS: We included 19 trials of 10 different NSAIDs. Overall, NSAIDs showed no effect on the CRP level (SMD 0.01 [95% CI -0.03, 0.06], P = 0.62). However, the prespecified stratified analysis indicated varying effects on the CRP level according to the different NSAIDs; lumiracoxib caused a statistically significant and consistent (I(2) = 0%) increase in the CRP level (SMD 0.13 [95% CI 0.01, 0.25], P = 0.037), whereas naproxen caused a statistically significant and consistent (I(2) = 0%) decrease in the CRP level (SMD -0.11 [95% CI -0.20, -0.02], P = 0.022). CONCLUSION: Overall, NSAIDs have no effect on the CRP level. However, the nonselective NSAID naproxen was associated with a significant decrease in the CRP level, whereas the cyclooxygenase 2-selective NSAID lumiracoxib was associated with a significant increase in the CRP level. This finding is interesting considering the suspected influence of NSAIDs on cardiovascular complications.
Authors: Scott D Nash; Karen J Cruickshanks; Ronald Klein; Barbara E K Klein; F Javier Nieto; Rick Chappell; Carla R Schubert; Michael Y Tsai Journal: J Am Geriatr Soc Date: 2013-07-26 Impact factor: 5.562
Authors: Jonathan Savitz; Martin P Paulus; Leandra K Figueroa-Hall; Bohan Xu; Rayus Kuplicki; Bart N Ford; Kaiping Burrows; T Kent Teague; Sandip Sen; Hung-Wen Yeh; Michael R Irwin Journal: Transl Psychiatry Date: 2022-07-12 Impact factor: 7.989
Authors: R S Redman; G S Kerr; J B Payne; T R Mikuls; J Huang; H R Sayles; K L Becker; E S Nylén Journal: Biotech Histochem Date: 2016 Impact factor: 1.718
Authors: Deborah Janowitz; Mohamad Habes; Jon B Toledo; Anke Hannemann; Stefan Frenzel; Jan Terock; Christos Davatzikos; Wolfgang Hoffmann; Hans Jörgen Grabe Journal: Brain Imaging Behav Date: 2020-08 Impact factor: 3.224
Authors: Rikke A Andreasen; Lars E Kristensen; Xenofon Baraliakos; Vibeke Strand; Philip J Mease; Maarten de Wit; Torkell Ellingsen; Inger Marie J Hansen; Jamie Kirkham; George A Wells; Peter Tugwell; Lara Maxwell; Maarten Boers; Kenneth Egstrup; Robin Christensen Journal: Arthritis Res Ther Date: 2020-07-25 Impact factor: 5.156
Authors: Anna C Rivara; Margaret Corley; Courtney C Choy; Rachel L Duckham; Alysa Pomer; Muagututia Sefuiva Reupena; Satupaitea Viali; Take Naseri; Erin E Kershaw; Scott E Crouter; Stephen T McGarvey; Richard G Bribiescas; Claudia Valeggia; Nicola L Hawley Journal: Am J Hum Biol Date: 2021-07-14 Impact factor: 1.937